Workflow
泓博医药(301230.SZ):2025年中报净利润为2476.14万元

Core Insights - The company, Hongbo Pharmaceutical (301230.SZ), reported a total revenue of 353 million yuan for the first half of 2025, ranking 28th among disclosed peers [1] - The net profit attributable to shareholders was 24.76 million yuan, placing the company 23rd among its peers [1] - The net cash inflow from operating activities was 39.43 million yuan, ranking 22nd among disclosed competitors [1] Financial Metrics - The latest debt-to-asset ratio is 21.85%, an increase of 0.44 percentage points from the previous quarter [3] - The gross profit margin stands at 27.93%, ranking 28th among peers, with a decrease of 0.46 percentage points from the last quarter [3] - The return on equity (ROE) is reported at 2.34% [3] - The diluted earnings per share (EPS) is 0.18 yuan [3] - The total asset turnover ratio is 0.26 times, while the inventory turnover ratio is 3.74 times [3] Shareholder Structure - The number of shareholders is 16,300, with the top ten shareholders holding a total of 83.60 million shares, accounting for 59.89% of the total share capital [3] - The largest shareholder is Hongbo Zhiyuan (Hong Kong) Pharmaceutical Technology Co., Ltd., holding 27.71% [3] - Other significant shareholders include An Rongchang (7.67%), Jiang Shengli (5.67%), and Shenyang Fubang Investment Co., Ltd. (5.22%) [3]